Medical News

RSS

Bowel cancer to cost $1 billion by 2011 – more emphasis on screening programs needed

Findings from a new study show that more and more Australians are being diagnosed with bowel cancer and costs of treatment may well touch $1 billion next year a sharp rise from the $235 million in 2001. The study says that there are more than 13,500 Australians diagnosed with bowel cancer each year.

1 Jun 2010

New technique transforms iPS cells into natural tumor killers

A technique for producing natural killer T (NKT) cells, known for their role in suppressing tumor growth, has been successfully demonstrated for the first time using induced pluripotent stem (iPS) cells. Developed by researchers at RIKEN, Japan’s flagship research institution, the technique opens the door to effective new cell-targeted treatments for cancer.

1 Jun 2010

AMA President to unveil multi-million dollar ad campaign

Today, the 21 percent Medicare physician payment cut goes into effect, leaving health care for seniors and military families in jeopardy. On June 3, AMA President J. James Rohack, MD, will hold a telephone news conference to unveil a multi-million dollar AMA ad campaign urging Americans to call their senators to help avoid a Medicare meltdown.

1 Jun 2010

Consent forms for research: Have they improved in 25 years?

The consent forms that people sign before participating in research are widely considered difficult to understand and sometimes inaccurate. The lack of clarity was implicated in a high-profile legal settlement in April between Arizona State University and a Native American tribe, which claimed that blood samples that its members provided for genetic research were used for purposes not stated in the consent form. Efforts have been made to improve the forms, but how effective are they?

1 Jun 2010

NanoPowers announces closing of CHF 5 million series A financing

NanoPowers SA, a medical device company that leverages its unique artificial muscle technology to restore or improve muscle function, today announced the closing of a CHF 5 million ($4.5 million) series A financing. The financing round was led by Novartis Venture Funds. Also participating in the financing were Initiative Capital Romandie and Gran Plasa SA.

1 Jun 2010

Protox announces presentations on PRX302 for BPH at 2010 AUA Annual Meeting

Protox Therapeutics Inc., a leader in the development of receptor targeted fusion proteins, today announced that two oral podium presentations on the company's lead candidate, PRX302, will be made at the 2010 Annual Meeting of the American Urological Association (AUA). These presentations will include six month data from the Phase 2b clinical study of PRX302 called TRIUMPH, in patients with moderate to severe benign prostatic hyperplasia (BPH).

1 Jun 2010

Belgian FAMHP approves Oncolytics' Phase 3 combination trial of REOLYSIN in head and neck cancers

Oncolytics Biotech Inc. today announced that it has received approval from the Belgian Federal Agency for Medicines and Health Products (FAMHP) to conduct its Phase 3 trial examining REOLYSIN in combination with paclitaxel and carboplatin in patients with platinum-refractory head and neck cancers. This is the same trial that was agreed to by U.S. Food and Drug Administration (FDA) under the Special Protocol Assessment (SPA) process and the U.K. Medicines and Healthcare products Regulatory Agency (MHRA).

1 Jun 2010

Enrollment and dosing in NeuroDerm's Phase I clinical trial of ND0611 completed

NeuroDerm, Ltd. announced today the successful enrollment and dosing in its Phase I clinical trial of ND0611. ND0611, a proprietary drug formula administered via a dermal patch, is designed to maintain continuous therapeutic levodopa concentrations for improving the treatment of Parkinson's disease.

1 Jun 2010

First Edition: June 1, 2010

A number of today's headlines focus on the continuing role of health reform in national political calculations and strategies.

1 Jun 2010

Europe spends just 5% of total cancer research funds on metastases

On average, about five percent of total cancer research funding is spent on investigating metastases (the spread of cancer cells around the body) in Europe, yet metastatic disease is the direct or indirect cause of 90 percent of all cancer deaths, according to an editorial in the European Journal of Cancer (EJC).

1 Jun 2010

PAREXEL International establishes new brand identity "Right Where You Need Us"

PAREXEL International Corporation, a leading global biopharmaceutical services provider, today announced that it has established the new brand identity "Right Where You Need Us," which reflects various transformation initiatives focused on meeting the diverse requirements of the Company's clients.

From Parexel 1 Jun 2010

OrthoDynamix releases disposable biter for meniscal shoulder, knee repair

OrthoDynamix announces a line extension to their sports medicine portfolio. The ArthroSteer Biter is the first ever disposable biter used for meniscal shoulder and knee repair. A sharp jaw for every procedure affords the ultimate tissue interaction. Moreover, the Biter is steerable, allowing access to and around joint capsule structures.

1 Jun 2010

New walk-in medical center opened in Duane Reade Pharmacy

If you have never been to a walk-in medical center at the local drugstore, you just might soon. Walk-in medical centers are already located in about 1,000 retail locations across the country, and experts say that number could easily double or more within five years.

1 Jun 2010

BioCryst to commence Phase 2 study of BCX4208 alone and in combination with allopurinol in gout patients

BioCryst Pharmaceuticals, Inc. announced it is initiating a Phase 2 study of BCX4208 alone and in combination with allopurinol in patients with gout. BioCryst recently reported positive results from part one of its Phase 2 monotherapy study of BCX4208 in patients with gout and is now moving forward as planned with an additional Phase 2 trial of BCX4208.

1 Jun 2010

GE Healthcare introduces new CESM technology to aid in breast cancer diagnosis

GE Healthcare, a pioneer in digital mammography, today announced the introduction of an innovative technology to aid in breast cancer diagnosis. GE Healthcare's new SenoBright Contrast Enhanced Spectral Mammography technology reduces ambiguity in mammography results, enabling physicians to detect and diagnose cancer with more confidence - even in the densest part of the breast tissue more rapidly and accurately.

1 Jun 2010

NHI, CFG enter loan participation agreement

National Health Investors, Inc. announced today it has agreed to provide funding of up to $20 million in a loan participation agreement with an affiliate of Capital Funding Group (CFG), a national leader in providing financing solutions for healthcare facilities.

1 Jun 2010

Targeted Genetics reports net income of $1.8M for fourth-quarter 2009 compared to net loss of $10.8M in 2008

Targeted Genetics Corporation today announced its financial results for the fourth quarter and full year ended December 31, 2009.

1 Jun 2010

AAPA honors Col. John W. Bullock with 2010 Federal Service PA of the Year Award

Col. John W. Bullock, PA-C, DFAAPA, of Falls Church, Va., received the American Academy of Physician Assistants' 2010 Federal Service PA of the Year Award at the organization's 38th Annual Physician Assistant Conference in Atlanta yesterday. He was honored for his groundbreaking work on behalf of physician assistants. His decisions on policy, clinical research and acquisition have helped enable the medical workforce both at home and overseas to provide quality, effective and accessible care in all kinds of environments.

1 Jun 2010

Donald M. Pedersen of Salt Lake City receives AAPA's 2010 Outstanding PA of the Year Award

Donald M. Pedersen, Ph.D., PA-C, of Salt Lake City, Utah, received the American Academy of Physician Assistants' 2010 Outstanding PA of the Year Award at the organization's 38th Annual Physician Assistant Conference in Atlanta yesterday. Pedersen has shaped PA education at the University of Utah School of Medicine for more than three decades, headed the implementation of the university's Master of PA Studies degree, and pioneered the program's international clinical activities in Papua New Guinea and Thailand.

1 Jun 2010

9th INT'L BIO FORUM & BIO EXPO JAPAN from June 30 - July 2, 2010

9th INT'L BIO FORUM & BIO EXPO JAPAN, organised by Reed Exhibitions Japan, will come back again as Asia's largest bio-event from June 30 - July 2, 2010. One of the hottest feature topics is "antibody drugs".

1 Jun 2010